Anti-inhibitor coagulant complex Side Effects
Medically reviewed by Drugs.com. Last updated on Sep 29, 2020.
For the Consumer
Applies to anti-inhibitor coagulant complex: intravenous powder for solution
Intravenous route (Powder for Solution)
Thromboembolic events have been reported during postmarketing surveillance following infusion of anti-inhibitor coagulant complex, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events.
Side effects requiring immediate medical attention
Along with its needed effects, anti-inhibitor coagulant complex may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking anti-inhibitor coagulant complex:
Incidence not known
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- chest pain or discomfort
- difficulty with swallowing
- fast heartbeat
- hives or welts
- joint pain, stiffness, or swelling
- pain in the injection site
- pain or discomfort in the arms, jaw, back, or neck
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- shortness of breath
- skin rash
- swelling of the eyelids, face, lips, hands, or feet
- tightness in the chest
- troubled breathing or swallowing
- unusual tiredness or weakness
For Healthcare Professionals
Applies to anti-inhibitor coagulant complex: intravenous powder for injection, intravenous solution
1. "Product Information. Autoplex T (anti-inhibitor coagulant complex)." Nabi, Boca Raton, FL.
More about anti-inhibitor coagulant complex
- Patient Information
- Anti-inhibitor coagulant complex Intravenous (Advanced Reading)
- Anti-inhibitor Coagulant Complex (Human)
Related treatment guides
Some side effects may not be reported. You may report them to the FDA.